Omaha researchers pulled in grants for drone cybersecurity and safer traffic stops as UNO smashed its own funding record.

Rides launched at 6 a.m. Monday, stretching from TCU to White Settlement, as federal regulators keep digging into Tesla's driving software.

A San Francisco Fed study says the brewing El Niño could nudge prices higher next year even as it boosts jobs.

A 73-year-old Valley woman once told she was not a surgery candidate is scheduled for her fourth session of a new tumor-burning treatment.

Larridin says it has optimized a median $2.4 million in AI spending per customer, though an independent profile questions the math.

Richmond's EKU wants to train doctors for Kentucky's most underserved counties, with the first graduates not expected until 2035.

A UH Mānoa study maps 17 rhodopsin proteins letting mantis shrimp see far-red light invisible to humans.

Dr. Reddy's generic lenacapavir could reach low-income countries by year's end, slashing a drug that costs $28,218 in the U.S. to just $40.

Mustafa Suleyman says there's zero evidence AI feels anything, while Anthropic keeps calling Claude's inner life an open question.

Setara emerged from Jazz Pharmaceuticals' Actio buyout with a TRPV4 drug now eyeing two very different diseases.

CO.LAB Q's first cohort tackles grid security, asset monitoring and making quantum computing usable, backed by Quantinuum and EPB.

The ChatGPT maker has secured $11 billion so far, with UAE investors expected to lead the scaled-back round.

The Tobaccoville-area maker now has 67 FDA-authorized nicotine pouches on the market, with eight new Velo varieties cleared Friday.